Elsevier

Survey of Ophthalmology

Volume 26, Issue 4, January–February 1982, Pages 207-218
Survey of Ophthalmology

Therapeutic review
Pharmacokinetics of topically applied ophthalmic drugs

https://doi.org/10.1016/0039-6257(82)90081-9Get rights and content

Abstract

Pharmacokinetic applications in recent years have led to significant advances in systemic drug therapy, but applications to topical, ophthalmic therapy have been far less numerous. Pharmacokinetics is the study of the time course of the absorption, distribution, metabolism, and elimination of an administered drug. Thus, it includes the quantitation of such elements of drug bioavailability as tear dilution, drug binding, and vehicle effects; factors affecting corneal absorption and subsequent tissue distribution; dosage form effects; and pathways of elimination. These factors are important because they significantly influence the clinical responses to administered drugs, in some instances to a profound degree. These elements and their clinical implications are discussed along with some recent applications, exemplified with data from studies on frequently prescribed drugs.

References (71)

  • TJ Mikkelson et al.

    Altered bioavailability of drugs in the eye due to drug protein interaction

    J Pharm Sci

    (1973)
  • TJ Mikkelson et al.

    Competitive inhibition of drug-protein interaction in eye fluids and tissues

    J Pharm Sci

    (1973)
  • S Mishima et al.

    The effect of normal evaporation on the eye

    Exp Eye Res

    (1961)
  • E Nelson

    Kinetics of drug absorption, distribution, metabolism, and excretion

    J Pharm Sci

    (1961)
  • TF Patton et al.

    Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes

    J Pharm Sci

    (1976)
  • RD Schoenwald et al.

    Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits

    J Pharm Sci

    (1980)
  • L Sendelbeck et al.

    Comparative distribution of pilocarpine in ocular tissues of the rabbit during administration by eyedrop or by membrane controlled delivery systems

    Am J Ophthalmol

    (1975)
  • SH Sherman et al.

    The fate of anterior fluorescein in the monkey eye. I. The anterior chamber pathways

    Exp Eye Res

    (1978)
  • JW Sieg et al.

    Mechanistic studies on transcorneal permeation of pilocarpine

    J Pharm Sci

    (1976)
  • JW Sieg et al.

    Vehicle effects on ocular drug bioavailability. I. Evaluation of fluorometholone

    J Pharm Sci

    (1975)
  • JW Sieg et al.

    Vehicle effects on ocular drug bioavailability. II. Evaluation of pilocarpine

    J Pharm Sci

    (1977)
  • JW Sieg et al.

    Vehicle effects on ocular drug bioavailability. III. Shear-facilitated pilocarpine release from ointments

    J Pharm Sci

    (1979)
  • K Swan et al.

    Corneal permeability. 1. Factors affecting penetration of drugs into the cornea

    Am J Ophthalmol

    (1942)
  • TJ Zimmerman et al.

    Timolol — Further observations

    Ophthalmology

    (1979)
  • I Abramovsky et al.

    Dipivefrin and echothiophate. Contraindications to combined use

    Arch Ophthalmol

    (1979)
  • RA Anderson et al.

    Influence of pH on the effect of pilocarpine on aqueous dynamics

    Br J Ophthalmol

    (1968)
  • SE Bloomfield et al.

    Soluble gentamycin ophthalmic inserts as a drug delivery system

    Arch Ophthalmol

    (1978)
  • WP Boger

    Timolol — short term escape and long term drift

    Ann Ophthalmol

    (1979)
  • HS Brown et al.

    Visual effects of pilocarpine in glaucoma. Comparative study of administration by eyedrops or by ocular therapeutic systems

    Arch Ophthalmol

    (1976)
  • R Brunish

    The protein components of human tears

    Arch Ophthalmol

    (1957)
  • SS Chrai et al.

    Drop size and initial dosing frequency problems of topically applied ophthalmic drugs

    J Pharm Sci

    (1974)
  • DG Cogan et al.

    The cornea VII: Permeability to weak electrolytes

    Arch Ophthalmol

    (1944)
  • SS Davis et al.

    The effect of ion-association on the transcorneal transport of drugs

    Br J Pharmacol

    (1978)
  • CH Dohlman et al.

    A new ocular insert device for continuous constant-rate delivery to the eye

    Ann Ophthalmol

    (1972)
  • FH Dost
  • Cited by (292)

    • Topical Ocular Therapeutics in Small Animals

      2023, Veterinary Clinics of North America - Small Animal Practice
    • Randomized Trial to Evaluate the Efficacy of the Nanodropper Device for Pupillary Dilation and Cycloplegia in Children

      2023, Ophthalmology
      Citation Excerpt :

      The problem of eye dropper medication waste is compounded for those with difficulty instilling eye drops. One study showed that, for every 1 drop properly instilled by a patient, 7 drops are wasted during the instillation attempt.1 Smaller-volume eye drops allow for greater administrative precision, which is particularly useful for pediatric patients who have difficulty with receiving eye drops.

    • An overview of nanocarriers used in corneal disease

      2023, Nanotechnology in Ophthalmology
    • Topical ocular drug delivery systems: Innovations for an unmet need

      2022, Experimental Eye Research
      Citation Excerpt :

      Smaller drop volumes may also result in a cost-saving for patients, as, in theory, fewer bottles of eye drops would be needed if no changes were made to the total volume of the drop bottles manufactured (Karki et al., 2011). The commonest form of topical ocular drug is aqueous solution eye drops, where all ingredients are completely dissolved within the solution (Shell, 1982). A pulse of drug delivery is achieved after the instillation, with subsequent rapid decline in drug concentration, with a kinetic profile similar to first order elimination (Souto et al., 2019).

    View all citing articles on Scopus
    View full text